Fatty liver disease affects a significant proportion of UK adults, whilst elevated eosinophils (a type of white blood cell) can signal various underlying conditions. When both abnormalities appear together on blood tests, patients naturally wonder whether fatty liver causes high eosinophils. Understanding the relationship between these findings is important for appropriate investigation and management. This article examines whether fatty liver disease directly causes eosinophilia, explores alternative explanations for concurrent abnormalities, and outlines when medical review is necessary. We also discuss the diagnostic approach recommended by NICE and UK specialist guidance.

Understanding Fatty Liver Disease and Eosinophil Levels

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. This condition exists in two main forms: non-alcoholic fatty liver disease (NAFLD), which affects people who drink little or no alcohol, and alcoholic fatty liver disease (AFLD), caused by excessive alcohol consumption. NAFLD is common in the UK, affecting an estimated 20–30% of adults, often associated with obesity, type 2 diabetes, and metabolic syndrome (NICE NG49). Some international guidance now uses the term metabolic dysfunction-associated steatotic liver disease (MASLD), though UK clinical pathways currently refer to NAFLD.

Eosinophils are a type of white blood cell that forms part of the body's immune system. Under normal circumstances, eosinophils comprise 1–4% of the total white blood cell count. In absolute terms, the normal range is typically less than 0.5 × 10⁹/L, though reference ranges may vary slightly between UK laboratories. These cells play a crucial role in fighting parasitic infections and are involved in allergic responses and inflammatory processes throughout the body.

Elevated eosinophil levels, known as eosinophilia, occur when the absolute count exceeds 0.5 × 10⁹/L. This elevation can be classified as mild (0.5–1.5 × 10⁹/L), moderate (1.5–5.0 × 10⁹/L), or severe (>5.0 × 10⁹/L). Hypereosinophilia is defined as a persistent eosinophil count of ≥1.5 × 10⁹/L on at least two occasions; when accompanied by organ involvement, this may indicate hypereosinophilic syndrome. Common causes of eosinophilia include allergic conditions such as asthma and eczema, parasitic infections, certain medications, and occasionally haematological disorders.

When patients present with both fatty liver disease and elevated eosinophils, it naturally raises questions about whether these conditions are connected. Understanding the relationship between liver pathology and immune cell abnormalities requires careful consideration of the underlying mechanisms, potential shared risk factors, and alternative explanations for concurrent findings. Both conditions are relatively common in the general population, which means their co-occurrence may sometimes be coincidental rather than causally related.

Can Fatty Liver Cause High Eosinophils?

Peripheral eosinophilia is not a recognised feature of fatty liver disease. NAFLD and AFLD primarily involve metabolic dysfunction and lipid accumulation within hepatocytes (liver cells), rather than triggering the specific immune responses that would elevate eosinophil production. The pathophysiology of fatty liver centres on insulin resistance, oxidative stress, and inflammatory pathways involving different immune cells, particularly macrophages and lymphocytes, rather than eosinophils.

Research examining the immune profile in fatty liver disease has not identified eosinophilia as a characteristic feature. The inflammatory process in NAFLD, particularly when it progresses to non-alcoholic steatohepatitis (NASH), involves elevated levels of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These mediators do not typically stimulate eosinophil production or recruitment in the way that interleukin-5 (IL-5) does in parasitic or allergic conditions.

Rare reports describe tissue eosinophilic infiltration in liver biopsies from patients with steatohepatitis, but this does not typically cause persistent peripheral eosinophilia. If you have both fatty liver disease and elevated eosinophils on blood tests, the eosinophilia should be investigated as a separate finding with its own potential causes.

It is important to recognise that patients with fatty liver disease may have elevated eosinophils for independent, unrelated reasons. Given that NAFLD affects a substantial proportion of the UK population, particularly those with metabolic syndrome, it is statistically likely that some individuals will have concurrent conditions affecting their eosinophil count. These might include allergic diseases, medication effects, parasitic infections, or other systemic conditions. A thorough clinical evaluation is warranted to identify the true cause of eosinophilia rather than assuming a connection with the liver pathology.

Common Causes of Elevated Eosinophils in Liver Conditions

Whilst fatty liver itself does not cause eosinophilia, several liver-related conditions and scenarios can be associated with elevated eosinophil counts. Understanding these helps clinicians and patients distinguish between coincidental findings and genuine pathological connections.

Drug-induced liver injury (DILI) represents one of the most important causes of eosinophilia in the context of liver disease. Certain medications can trigger hypersensitivity reactions affecting both the liver and the immune system. Drugs commonly implicated include antibiotics (particularly beta-lactams and sulphonamides), anti-epileptic medications (such as phenytoin and carbamazepine), allopurinol, and some non-steroidal anti-inflammatory drugs (NSAIDs). A severe form of drug hypersensitivity, DRESS (drug reaction with eosinophilia and systemic symptoms), presents with rash, fever, lymphadenopathy, eosinophilia, and organ involvement (including liver injury), typically 2–8 weeks after starting a new medicine. DRESS requires urgent medical assessment and immediate cessation of the causative drug under medical supervision. The MHRA maintains pharmacovigilance data on such reactions. If you suspect a medicine has caused side effects, report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Parasitic infections affecting the liver can cause marked eosinophilia. Conditions such as hepatic fascioliasis (liver fluke infection), toxocariasis, and schistosomiasis may present with liver involvement and significantly elevated eosinophil counts. Whilst less common in the UK than in tropical regions, these infections should be considered in patients with relevant travel history or dietary exposures (such as consumption of watercress in endemic areas for liver fluke). Stool microscopy may have low sensitivity; multiple samples (typically 2–3) and targeted serology based on exposure history improve detection. If eosinophilia and relevant exposure are present, it is important to evaluate and treat Strongyloides infection before starting systemic corticosteroids, as this can lead to life-threatening hyperinfection.

Primary biliary cholangitis (PBC) and other autoimmune liver conditions very rarely demonstrate mild eosinophilia, though this is not a defining or common feature. Eosinophilic infiltration of the liver, though rare, can occur as part of hypereosinophilic syndrome or eosinophilic gastroenteritis with hepatic involvement.

Additionally, patients with chronic liver disease may develop portal hypertension and hypersplenism, which can alter blood cell counts, though this typically causes cytopenias (low counts) rather than eosinophilia. Concurrent allergic conditions, asthma, or atopic diseases remain the most frequent explanation for elevated eosinophils in patients who happen to have fatty liver disease.

When to Seek Medical Advice for Abnormal Blood Results

If you have received blood test results showing elevated eosinophils, particularly in combination with known or suspected fatty liver disease, it is important to discuss these findings with your GP. Do not attempt to self-diagnose or ignore abnormal results, as they may indicate conditions requiring investigation or treatment.

You should seek medical advice promptly if you experience any of the following alongside abnormal blood results:

• Jaundice (yellowing of the skin or whites of the eyes) — new adult jaundice requires urgent same-day clinical assessment, as it may indicate significant liver dysfunction

• Persistent abdominal pain, particularly in the right upper quadrant where the liver is located

• Unexplained weight loss, fever, or night sweats, which could suggest infection or other systemic illness

• Severe itching (pruritus), which can occur in various liver and allergic conditions

• New or worsening allergic symptoms, including rash, breathing difficulties, or swelling

• Dark urine or pale stools, indicating possible bile duct involvement

• New rash and fever after starting a medicine, which may indicate a serious drug hypersensitivity reaction requiring urgent medical review

Seek urgent medical attention (contact 111 or attend A&E) if you develop severe abdominal pain, confusion, vomiting blood, or black tarry stools, as these may indicate serious complications.

For routine abnormal results without concerning symptoms, arrange an appointment with your GP within one to two weeks. Your doctor will take a comprehensive history, including:

• Current and recent medications (including over-the-counter drugs and supplements)

• Travel history, particularly to tropical or subtropical regions

• Dietary exposures and potential contact with contaminated water or food

• Symptoms of allergic conditions or asthma

• Alcohol consumption patterns

• Family history of liver disease or blood disorders

Your GP may repeat blood tests to confirm the findings and assess trends over time. Isolated mild elevations in eosinophils are common and often resolve spontaneously. However, persistent eosinophilia ≥1.5 × 10⁹/L, any eosinophil count >5.0 × 10⁹/L, or eosinophilia with organ dysfunction or systemic symptoms warrants prompt specialist review, typically by haematology. The approach will be tailored to your individual clinical picture, considering both the degree of eosinophilia and any liver function abnormalities.

Diagnostic Tests for Fatty Liver and High Eosinophils

When both fatty liver and elevated eosinophils are identified, a systematic diagnostic approach helps determine whether these findings are related and identifies any underlying conditions requiring treatment. NICE guidance on NAFLD (NG49, DG34) and British Society for Haematology (BSH) guidance on eosinophilia inform the clinical pathway.

For fatty liver disease assessment, initial investigations typically include:

• Liver function tests (LFTs): measuring alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, and albumin. In NAFLD, ALT is often mildly elevated (typically less than twice the upper limit of normal), though normal LFTs do not exclude fatty liver.

• Aetiology screen: to exclude other causes of liver disease, including hepatitis B surface antigen, hepatitis C antibody (with PCR if indicated), autoimmune antibodies (antinuclear antibodies [ANA], anti-smooth muscle antibodies [ASMA], anti-mitochondrial antibodies [AMA]), ferritin and transferrin saturation (to assess iron overload), and consideration of coeliac serology if appropriate

• Metabolic screening: fasting glucose or HbA1c, lipid profile (cholesterol and triglycerides), and assessment for metabolic syndrome components

• Liver ultrasound: the first-line imaging modality for detecting hepatic steatosis, showing increased echogenicity of the liver parenchyma

• Non-invasive fibrosis assessment: the FIB-4 score is calculated from age, ALT, AST, and platelet count. NICE recommends: FIB-4 <1.3 (or <2.0 if aged >65) indicates low risk of advanced fibrosis and can be managed in primary care; FIB-4 1.3–3.25 (or 2.0–2.67 if >65) is indeterminate and should prompt Enhanced Liver Fibrosis (ELF) blood test; FIB-4 >3.25 (or >2.67 if >65) or elevated ELF indicates high risk and warrants referral to hepatology

• Transient elastography (FibroScan): increasingly available in secondary care, this measures liver stiffness as a marker of fibrosis

Referral to hepatology is recommended for persistent abnormal liver blood tests, suspected advanced fibrosis or cirrhosis, or when alternative liver disease aetiologies are identified.

For investigating eosinophilia, the diagnostic approach depends on the degree of elevation and clinical context:

• Repeat full blood count with differential: to confirm persistent eosinophilia and assess other cell lines

• Peripheral blood film: to evaluate eosinophil morphology and exclude other haematological abnormalities

• Comprehensive medication review: identifying any drugs started within the preceding 2–12 weeks that might cause hypersensitivity

• Parasitic screening: stool microscopy for ova, cysts, and parasites (typically 2–3 samples to improve sensitivity); serology for strongyloides, schistosomiasis, and other helminths if travel history or relevant exposures are present

• Allergy assessment: total IgE levels, specific allergen testing if allergic disease is suspected

• Inflammatory markers: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)

• Chest X-ray: if respiratory symptoms are present

• Autoimmune screening: if autoimmune liver disease is considered, tests may include ANA, AMA, and ASMA

In cases of moderate to severe eosinophilia (≥1.5 × 10⁹/L persistent, or >5.0 × 10⁹/L, or any eosinophilia with organ involvement or unexplained systemic symptoms), referral to haematology is appropriate to exclude primary eosinophilic disorders or haematological malignancies. Additional investigations might include bone marrow examination, flow cytometry, and targeted molecular testing (e.g., FIP1L1-PDGFRA fusion gene) for conditions such as chronic eosinophilic leukaemia.

If drug-induced liver injury with eosinophilia is suspected, the implicated medication should be stopped under medical supervision, and liver function monitored closely. Most cases of DILI resolve following drug withdrawal, though severe cases (including DRESS) may require specialist hepatology input and supportive care.

The integration of findings from both liver and haematological investigations allows clinicians to determine whether the conditions are coincidental, share common risk factors (such as medication effects), or represent distinct pathologies requiring separate management strategies. Patient safety is paramount, and any uncertainty should prompt specialist referral to hepatology or haematology services as appropriate.

Frequently Asked Questions